After getting smallpox vaccine ACAM2000 from Sanofi and an anthrax treatment called raxibacumab from GlaxoSmithKline, Emergent BioSolutions is buying again, this time an entire company: PaxVax.
In an all-cash deal worth $270 million, Maryland-based Emergent, a vaccine company that has focused on biodefense, will buy California-headquartered specialty vaccine maker PaxVax, which also has close ties with the government.
{iframe}https://www.fiercepharma.com/vaccines/emergent-biosolutions-to-acquire-paxvax-and-two-travelers-vaccines-270m-deal{/iframe}